

ADVANCING THE MANAGEMENT OF PROSTATE CANCER-RELATED BONE DISEASE



Release date: July 2010

Expiration date: July 31, 2011

Estimated time to complete activity: 2 hours

Jointly sponsored by Curatio CME Institute, the Bone and Cancer Foundation, and the Cancer and Bone Society.

This CME-certified podcast contains audio from presentations given at a satellite symposium held prior to the 2010 American Urological Association (AUA) Annual Meeting.

This activity is supported by an educational donation provided by Amgen.

Hardware/Software Requirements

- Adobe Acrobat Reader
- mp3 audio player



Activity Overview

Prostate cancer is the most common newly diagnosed cancer in men. In the U.S., prostate cancer accounts for 25% of all new cancer diagnoses and 10% of all cancer deaths. Prostate cancer also has a high propensity for metastasizing to bone, at which time it is considered incurable and is associated with a high degree of morbidity and mortality. The increased bone loss and associated skeletal complications that result from cancer and cancer therapies are equally concerning, even in patients without metastasis. This activity discusses the current and emerging therapies used to improve the management of bone disease in men with prostate cancer. Emerging clinical trial data is also discussed.

Target Audience

This activity has been designed to meet the educational needs of urologists, urologic oncologists, medical oncologists, and other health care providers who manage patients with prostate cancer that has metastasized to bone or has the potential to metastasize to bone.

Learning Objectives

At the conclusion of this activity, participants should be able to:

- Describe the clinical impact of untreated bone loss on fracture risk, overall health, quality of life, and survival
- Discuss mechanisms of bone loss and new therapeutic approaches for managing bone loss

- Recommend appropriate screening methods and schedules to monitor for bone loss
- Utilize evidence-based practices in the prevention and management of bone disease
- Educate patients with clear, concise information on the risks associated with various bone-sparing agents and the risks of complications associated with a lack of treatment

Activity Faculty

Matthew R. Smith, MD, PhD—Chair

Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Celestia S. Higano, MD

Professor of Medicine
Division of Oncology and Department of Urology
University of Washington
Seattle, Washington

Joel B. Nelson, MD

Frederic N. Schwentker Professor and Chairman
Department of Urology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Fred Saad, MD, FRSC

Professor and Chief of Urology
Director of Urologic Oncology
University of Montreal Endowed Chair in Prostate Cancer
University of Montreal Hospital Centre
University of Montreal
Montreal, Quebec, Canada

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Curatio CME Institute, the Bone and Cancer Foundation, and the Cancer and Bone Society. Curatio CME Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Curatio CME Institute designates this educational activity for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in this CME activity. To receive credit during the period July 2010 to July 31, 2011, participants must (1) read the learning objectives and disclosure statements, (2) listen to the podcast, and (3) complete the activity evaluation form, including the participation attestation statement.

The activity evaluation can be accessed by going to <http://www.BoneOncologyTX.com>. Please e-mail any questions to cmeinfo@curatiocme.com.

Clinicians should not claim credit for this activity if credit was previously claimed for the symposium on which this activity is based.

Medium

A podcast was selected as the instructional format to allow participants to learn on their own time and at their own pace.

Disclosure

In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Celestia S. Higano, MD, has disclosed the following relevant financial relationship:
Speaker Amgen

Dr. Higano discusses the unlabeled or investigational use of a commercial product.

Joel B. Nelson, MD, has disclosed the following relevant financial relationships:
Speaker Astra Zeneca
Consultant Amgen, Millennium/Takeda, Roche

Fred Saad, MD, FRSC, has disclosed the following relevant financial relationships:
Speaker, Consultant Amgen, Novartis

Matthew R. Smith, MD, PhD, has disclosed the following relevant financial relationships:
Consultant Amgen, GTx, Novartis

Dr. Smith discusses the unlabeled or investigational use of a commercial product.

Curatio CME Institute

Matthew Horn, MD, Medical Director, has disclosed no relevant financial relationships.

Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.

Derek Warnick, CME Director, has disclosed no relevant financial relationships.

Bone and Cancer Foundation

Charlene Waldman, Executive Director, has disclosed no relevant financial relationships.

Cancer and Bone Society

Jeanette Ruby, Director of Development, has disclosed no relevant financial relationships.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, the Bone and Cancer Foundation, the Cancer and Bone Society, and Amgen do not recommend the use of any agent outside the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, the Bone and Cancer Foundation, the Cancer and Bone Society, or Amgen. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Policy on Privacy and Confidentiality

Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.

Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.